Public preview. Funding rounds, founders, and growth signals require a free account.

Halia Therapeutics, Inc.

Halia Therapeutics identifies protective genetic factors that help individuals resist disease by analyzing population-scale pedigrees and genetic data, then develops drug candidates targeting these resilience mechanisms across neurology, metabolism, and oncology. The company's clinical programs include treatments for Alzheimer's disease, metabolic immune deficiency syndrome, and obesity, with lead candidates targeting genes like RAB10 and NEK7.

Series BBiotechSalt Lake City, UT11-50 employees

Total raised

$23.9M

Last round

Equity

$337K · Jul 2025

Stage

Series B

Status

Active

Founders & team

Co-founder, CEO

Co-founder, CTO

Head of Engineering

Head of Sales

🔒

Sign up to see founders

Free account unlocks founder names, LinkedIn profiles, and prior companies.

Create free account

Growth signals

Web traffic

Search interest

Social followers

Glassdoor rating

News mentions

Gov contracts

🔒

Sign up to see signals

Free account unlocks 5 full profiles per day. Pro removes the limit.

Create free account

Track Halia Therapeutics, Inc. on FlareSight

Get notified the moment Halia Therapeutics, Inc. files a new round, hires execs, or shows traction signals.

Create free account

About this data

FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.